Correlation of Blood Cell Parameters and Severity of Symptom Burden and Quality of Life Among Individuals with Philadelphia-Negative Myeloproliferative Neoplasia: A Sub-Study of the Filipino MPN-QOL Multicenter Study

Jacqueline Rose E. Agustin, Flordeluna Z. Mesina

Apr 2025 DOI 10.35460/2546-1621.2024-0006     Access   

Abstract

Rationale and Objectives: Individuals with myeloproliferative neoplasia (MPN) have blood cell parameters representing abnormal proliferation of the cell line/lines affected. Considering the implication of symptom burden scores to treatment response and disease progression, with the same implication among changes in blood cell parameters, a question of correlation between the two variables becomes inevitable. This study aims to determine the correlation of controlled blood counts, severity of symptoms and quality of life of individuals with MPN. 

Research Design and Methodology: This is a cross-sectional analytical study and a sub-study from the Filipino myeloproliferative neoplasia quality of life (MPN-QOL) multicenter study. Secondary data obtained from the parent study will be used as primary data of this sub-study. Comparative analyses were conducted using Chi-Square Test of Homogeneity or Fisher’s Exact Test. Association analysis used Cramer’s V coefficient. 

Results: Data in this study has shown 52.65 years old as the average age of participants. Most participants had mild symptom burden at 60.53% with the most common symptom being fatigue. Comparative analysis showed the absence of identified statistical difference in the overall symptom burden severity among the three types of MPN. 

Discussion and Conclusion: In this study, there was no statistically significant correlation between the severity of symptom burden or quality of life, and the degree of blood count control among the three types of MPN. In practice, controlling hematologic parameters has been a goal to achieve among patients with MPN. This study suggests symptom control and quality of life is not necessarily affected by blood count control. 

Keywords: Myeloproliferative neoplasia, polycythemia vera, essential thrombocythemia, myelofibrosis, blood count control, symptom burden, quality of life 

  1. Wilkins BS. Myeloproliferative neoplasms. Diagn Histopathol (Oxf) [Internet]. 2021;27(9):373–9. Available from: http://dx.doi.org/10.1016/j.mpdhp.2021.06.003 
  2. Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, et al. Symptom burden and blood counts in patients with polycythemia vera in the United States: An analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk [Internet]. 2019;19(9):579-584.e1. Available from: http://dx.doi.org/10.1016/j.clml.2019.06.001 
  3. Yassin MA, Taher A, Mathews V, Hou H-A, Shamsi T, Tuğlular TF, et al. MERGE: A multinational, multicenter observational registry for myeloproliferative neoplasms in Asia, including Middle East, Turkey, and Algeria. Cancer Med [Internet]. 2020;9(13):4512–26. Available from: http://dx.doi.org/10.1002/cam4.3004 
  4. Iurlo A, Cattaneo D, Bucelli C, Baldini L. New perspectives on polycythemia vera: From diagnosis to therapy. Int J Mol Sci [Internet]. 2020;21(16):5805. Available from: http://dx.doi.org/10.3390/ijms21165805 
  5. Ashorobi D, Gohari P. Essential thrombocytosis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
  6. Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood [Internet]. 2016;128(20):2403–14. Available from: http://dx.doi.org/10.1182/blood-2016-05-643346 
  7. Tefferi A. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management. Am J Hematol [Internet]. 2021;96(1):145–62. Available from: http://dx.doi.org/10.1002/ajh.26050 
  8. Cervantes F. How I treat myelofibrosis. Blood [Internet]. 2014;124(17):2635–42. Available from: http://dx.doi.org/10.1182/blood-2014-07-575373 
  9. Geyer H, Mesa RA. Approach to MPN symptom assessment. Curr Hematol Malig Rep [Internet]. 2017;12(5):381–8. Available from: http://dx.doi.org/10.1007/s11899-017-0399-5 
  10. Emanuel RM, Dueck AC, Geyer HL, Kiladjian J-J, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol [Internet]. 2012;30(33):4098–103. Available from: http://dx.doi.org/10.1200/JCO.2012.42.3863 
  11. Ting FI, Callueng JM, Vallente J, Hurtado RA, Ramirez A, Catedral LI, et al. Assessing the quality of life of Filipino cancer patients: A survey of Filipino oncologists. Asian J Oncol [Internet]. 2020;6(01):20–8. Available from: http://dx.doi.org/10.1055/s-0040-1703420 
  12. Harrison CN, Koschmieder S, Foltz L, Guglielmelli P, Flindt T, Koehler M, et al. The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN landmark survey. Ann Hematol [Internet]. 2017;96(10):1653–65. Available from: http://dx.doi.org/10.1007/s00277-017-3082-y 
  13. Spivak JL. How I treat polycythemia vera. Blood [Internet]. 2019;134(4):341–52. Available from: http://dx.doi.org/10.1182/blood.2018834044 
  14. Campbell PJ, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian J-J, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood [Internet]. 2012;120(7):1409–11. Available from: http://dx.doi.org/10.1182/blood-2012-04-424911 
  15. Buxhofer-Ausch V, Steurer M, Sormann S, Schloegl E, Schimetta W, Gisslinger B, et al. Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia. Eur J Haematol [Internet]. 2018;131–5. Available from: http://dx.doi.org/10.1111/ejh.13070 
  16. Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood [Internet]. 2013;122(8):1395–8. Available from: http://dx.doi.org/10.1182/blood-2013-03-488098 
  17. Daniel WW, Cross CL. Biostatistics: A Foundation for Analysis in the Health Sciences. 10th ed. New Jersey, USA: Wiley; 2013.
  18. Allen M. The SAGE encyclopedia of communication research methods [Internet]. 2455 Teller Road, Thousand Oaks California 91320: SAGE Publications, Inc; 2017. Available from: http://dx.doi.org/10.4135/9781483381411 
  19. Lautert L. Professional fatigue: empirical study with hospital nurses. Rev Gaucha Enferm. 1997;18(2):133–44.
  20. Pera G, Serra-Prat M. Burnout syndrome: prevalence and associated factors among workers in a district hospital. Gac Sanit [Internet]. 2002;16(6):480–86. Available from: http://dx.doi.org/10.1016/s0213-9111(02)71968-7 
  21. Ruste SA, Ngelangel C. QoL of colorectal cancer stoma patients at the Philippine General Hospital - Cancer Institute. Philippine Journal of Internal Medicine. 2011;49(1):38–41.
  22. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian J-J, Lengfelder E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood [Internet]. 2013;121(23):4778–81. Available from: http://dx.doi.org/10.1182/blood-2013-01-478891 
  23. Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, et al. Comprehensively understanding fatigue in patients with myeloproliferative neoplasms: Myeloproliferative neoplasm fatigue. Cancer [Internet]. 2016;122(3):477–85. Available from: http://dx.doi.org/10.1002/cncr.29753 
  24. Lelonek E, Matusiak Ł, Wróbel T, Szepietowski JC. Aquagenic pruritus in polycythemia vera: Clinical characteristics. Acta Derm Venereol [Internet]. 2018;98(5):496–500. Available from: http://dx.doi.org/10.2340/00015555-2906 

Articles related to the one you are viewing

There are currently no results to show, please try again later

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits use, share — copy and redistribute the material in any medium or format, adapt — remix, transform, and build upon the material, as long as you give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original. You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc-sa/4.0/.